|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the multivariable Cox regression analysis, elevated cTnI was an independent predictor of all-cause death (hazard ratio, 1.95, 95% confidence interval: 1.08-3.50, P = 0.026), in addition to age and prior heart failure.
|
30895632 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main manifestations of these 51 patients with AMI were as follows: the serum levels of myocardial injury markers (creatine kinase-Mb [CK-Mb] and cardiac troponin I [cTnI]) and heart failure markers (N-terminal pro B-type natriuretic peptide [NT-pro BNP]) were significantly higher, when compared with the control group (P < .001), and the incidence of arrhythmia (FVPB, P = .02; RAA, P = .03; RVA, P = .02; ST-T changes, P = .01) and heart failure (P = .04) was also significantly higher when compared with the control group.
|
30732172 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The workup of patients with spontaneous ICH should involve 12-lead ECG, cardiac troponin-I, as well as BNP, and echocardiogram to evaluate for heart failure.
|
29389729 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early detection of cardiac troponin I (cTnI), B-type natriuretic peptide (BNP), and myoglobin (Myo) is essential for the diagnosis of acute myocardial infarction (AMI) and heart failure (HF).
|
30985109 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the case of BNP-32, the sensor developed has a linear response from 1 pg mL<sup>-1</sup> to 1 μg mL<sup>-1</sup> in serum; for cTnI, linearity is observed from 1 pg mL<sup>-1</sup> to 10 ng mL<sup>-1</sup> as demanded for early-stage diagnosis of heart failure.
|
30320285 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
|
30571192 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heart Failure-Related Hyperphosphorylation in the Cardiac Troponin I C Terminus Has Divergent Effects on Cardiac Function In Vivo.
|
28899987 |
2017 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the current lack of biomarkers in HF with preserved ejection fraction (HFpEF), we aimed to investigate the prognostic performance of the newly developed high-sensitivity (hs) assays for cardiac troponin I (hsTnI) compared with troponin T (hsTnT) for adverse events in HFpEF vs. HF with reduced ejection fraction (HFrEF).
|
28849609 |
2017 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis.
|
18955666 |
2008 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clinical manifestations of CTnI mutations that cause FHC are diverse, ranging from asymptomatic with high life expectancy to severe heart failure and sudden cardiac death.
|
15524171 |
2004 |